ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 626

Radiographic Progression of Structural Joint Damage in Patients with Active Psoriatic Arthritis Treated with Ixekizumab over 52 Weeks

Désirée van der Heijde1, Masato Okada2, Chin H. Lee3, Catherine Shuler3, Suchitrita Rathmann3, Chen-Yen Lin3 and Philip J Mease4, 1Leiden University Medical Center, Leiden, Netherlands, 2Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, 3Eli Lilly and Company, Indianapolis, IN, 4Swedish Medical Center and University of Washington, Seattle, WA

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Biologics, interleukins (IL), joint damage and psoriatic arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 5, 2017

Title: Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Ixekizumab (IXE), an anti-interleukin-17A monoclonal antibody, was shown to be superior to placebo (PBO) in clinical responses and inhibiting the progression of structural joint damage in patients with PsA treated for 24 weeks (wks).1 The objective was to assess the progression of structural joint damage in PsA pts with IXE for up to 52 wks.

Methods: Biologic DMARD-naïve pts with active PsA (N=417) entered into SPIRIT-P1 (NCT01695239), a double-blind phase 3 trial. Pts must have had ≥1 joint erosion on the hand and foot x-rays confirmed by central reading or had a C-reactive protein level >6 mg/L at screening. 417 pts were randomized to IXE 80 mg every 2 wks (Q2W; N=103) or 4 wks (Q4W; N=107) following a 160 mg initial dose, PBO (N=106), or adalimumab 40 mg every 2 wks (ADA; active reference arm; N=101) for 24 wks. In the Extension period (EXT: Wks 24-52), PBO and ADA pts were re-randomized (1:1) to IXEQ2W or IXEQ4W at Wk 16 (inadequate responders) or Wk 24; ADA pts underwent a washout prior to IXE treatment. All pts were assessed for structural joint damage using the van der Heijde-modified PsA Total Sharp Score (mTSS, 0-528 scale). X-rays at Wks 0, 24, and 52 were scored independently by 2 readers blinded to time point and clinical data (average of readers). mTSS was excluded from the pre-specified analysis if the radiograph was taken after the scheduled visit date. In a post hoc analysis, mTSS from a radiograph taken after the scheduled visit date was interpolated and considered as observed data. Any missing data at Wk 52, in either presentation, were imputed using a linear extrapolation if they had at least 1 post-baseline value.

 

Results: Pts had active PsA at Wk 0 (Table). 381 pts (91.3%) entered the EXT, with 374 (98.2%) having radiographs collected during the EXT. Wk 52 mean (SD) mTSS change from baseline were 0.54 (2.11) and 0.09 (1.0) for pts randomized to IXEQ4W and IXEQ2W at baseline, respectively. Similar changes at Wk 52 were obtained with the post hoc analysis (Table). The majority of IXEQ2W or IXEQ4W pts exhibited no structural progression through 1 year of IXE treatment (Figure). In pts who switched from PBO or ADA to IXE, Wk 52 mean change from baseline mTSS values scores ranged from -0.03 to 0.41 (Table).

Conclusion: Over a 52-wk period, minimal changes in mTSS were observed in PsA pts entering the EXT and treated with IXEQ2W or IXEQ4W.

1.    Mease P et al. 2017 ARD 76(1):79


Disclosure: D. van der Heijde, AbbVie, Amgen, Astellas, AstraZeneca, BMS, Boehringer Ingelheim, Celgene, Daiichi, Eli-Lilly, Galapagos, Gilead, Glaxo-Smith-Kline, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda, UCB, 5,Leiden University Medical Centre, 3; M. Okada, St. Luke's International University, 3; C. H. Lee, Eli Lilly and Company, 3; C. Shuler, Eli Lilly and Company, 3; S. Rathmann, Eli Lilly and Company, 3; C. Y. Lin, Eli Lilly and Company, 1,Eli Lilly and Company, 3; P. J. Mease, Abbvie, Amgen, Bristol Myers Aquibb, Celgene, Genentech, Janssen, Novartis, Pfizer, UCB, 8,Abbvie, Amgen, Bristol Myers Aquibb, Celgene, Lilly, Janssen, Novartis, Pfizer, UCB, Sunpharma, 9,Abbvie, Amgen, Celgene, Lilly, Janssen, Novartis, Pfizer, UCB, 9.

To cite this abstract in AMA style:

van der Heijde D, Okada M, Lee CH, Shuler C, Rathmann S, Lin CY, Mease PJ. Radiographic Progression of Structural Joint Damage in Patients with Active Psoriatic Arthritis Treated with Ixekizumab over 52 Weeks [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/radiographic-progression-of-structural-joint-damage-in-patients-with-active-psoriatic-arthritis-treated-with-ixekizumab-over-52-weeks/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/radiographic-progression-of-structural-joint-damage-in-patients-with-active-psoriatic-arthritis-treated-with-ixekizumab-over-52-weeks/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology